Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
65.11
-0.66 (-1.00%)
At close: Dec 18, 2025, 4:00 PM EST
64.87
-0.24 (-0.37%)
After-hours: Dec 18, 2025, 5:28 PM EST
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
$3,551,006
Profits / Employee
$1,701,406
Market Cap
7.66B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HALO News
- 12 hours ago - U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - PRNewsWire
- 3 days ago - Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha
- 10 days ago - Jim Lang Elected to Halozyme's Board of Directors - PRNewsWire
- 14 days ago - Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case - WSJ
- 14 days ago - Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany - PRNewsWire
- 16 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - PRNewsWire
- 4 weeks ago - Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery - PRNewsWire